Heightened vulnerability to MDR-TB epidemics after controlling drug-susceptible TB

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-11

  Bishai, Jason D ^a   Bishai, William R ^b   Bishai, David M ^c  

^a STANFORD UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; COMPUTER SIMULATION; EPIDEMIC; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PREVALENCE; RISK ASSESSMENT; RISK REDUCTION; TUBERCULOSIS CONTROL; BIOLOGICAL MODEL; HUMAN;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; EPIDEMICS; HUMANS; MODELS, BIOLOGICAL; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77958512046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012843     Document Type: Article

References (37)

1. WHO (2008) Anti-tuberculosis drug resistance in the world. Geneva: World Health Organization.
2. Mitnick CD, Appleton SC, Shin SS (2008) Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med 29: 499-524.
3. Schneider E, Moore M, Castro KG (2005) Epidemiology of tuberculosis in the United States. Clin Chest Med 26: 183-195, v.
4. Burzynski J, Schluger NW (2008) The epidemiology of tuberculosis in the United States. Semin Respir Crit Care Med 29: 492-498.
5. Shilova MV (2001) Specific features of the spread of tuberculosis in Russia at the end of the 20th century. Ann N Y Acad Sci 953: 124-132.
6. Yerokhin VV, Punga VV, Rybka LN (2001) Tuberculosis in Russia and the problem of multiple drug resistance. Ann N Y Acad Sci 953: 133-137.
7. Grange JM, Gandy M, Farmer P, Zumla A (2001) Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberc Lung Dis 5: 208-212.
8. Joesoef M, Remington P, Jiptoherijanto P (1989) Epidemiological Model and Cost-Effectiveness Analysis of Tuberculosis Treatment Programmes in Indonesia. Int J Epidemiol 18: 174-179.
9. Sawert H, Kongsin S, Payanandana V, Akarasewi P, Nunn P, et al. (1997) Costs and Benefits of Improving Tuberculosis Control: The Case of Thailand. Social Science and Medicine 44: 1805-1816.
10. Dye C, Fengzeng Z, Scheele S, Williams B (2000) Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 29: 558-564.
11. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, et al. (1995) The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1: 815-821.
12. Grzybowski S, Styblo K, Dorken E (1976) Tuberculosis in Eskimos. Tubercle 57: S1-S58.
13. Stott H, Patel A, Sutherland I, Thorup I, Smith PG, et al. (1973) The risk of tuberculosis infection in Uganda, derived from the findings of national tuberculin surveys in 1958 and 1970. Tubercle 54: 1-22.
14. Styblo K (1991) Epidemiology of Tuberculosis. The Hague: Royal Netherlands Tuberculosis Association.
15. Glaziou P (2006) Mathematical modeling of the TB epidemic in the Western Pacific Region. Manila: WHO/WPRO.
16. Blower SM, Gerberding JL (1998) Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J Mol Med 76: 624-636.
17. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10: 1117-1121.
18. Dye C, Espinal MA (2001) Will tuberculosis become resistant to all antibiotics? Proc Biol Sci 268: 45-52.
19. Wilensky U (1999) NetLogo. EvanstonIL: Northwestern University.
20. Cohen T, Sommers B, Murray M (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 3: 13-21.
21. Balabanova Y, Fedorin I, Kuznetsov S, Graham C, Ruddy M, et al. (2004) Antimicrobial prescribing patterns for respiratory diseases including tuberculosis in Russia: a possible role in drug resistance? J Antimicrob Chemother 54: 673-679.
22. Richardson M, Carroll NM, Engelke E, Van Der Spuy GD, Salker F, et al. (2002) Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-incidence community setting. J Clin Microbiol 40: 2750-2754.
23. Fine PE, Small PM (1999) Exogenous reinfection in tuberculosis. N Engl J Med 341: 1226-1227.
24. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, et al. (1999) Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 341: 1174-1179.
25. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, et al. (1993) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328: 1137-1144.
26. Gagneux S, Long CD, Small PM, Van T, Schoolnik, GK., et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944-1946.
27. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL (2003) Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis 188: 1878-1884.
28. Shafer RW, Small PM, Larkin C, Singh SP, Kelly P, et al. (1995) Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. J Infect Dis 171: 170-176.
29. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
30. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
31. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
32. Ginsberg AM (2008) Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 29: 552-559.
33. Cohen T, Colijn C, Finklea B, Murray M (2007) Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J R Soc Interface 4: 523-531.
34. Roberts C, Buikstra J (2003) The Bioarcheology of Tuberculosis: A Global View on a Reemerging Disease. GainesvilleFL: University Press of Florida. 118 p.
35. Bloom BR, Murray CJ (1992) Tuberculosis: commentary on a reemergent killer. Science 257: 1055-1064.
36. Blower SM, Chou T (2004) Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 10: 1111-1116.
37. Murray CJ, Styblo K, Rouillon A (1990) Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 65: 6-24.